Why TDP-43? Why not? Mechanisms of metabolic dysfunction in amyotrophic lateral sclerosis by Floare, M.-L. & Allen, S.P.
This is a repository copy of Why TDP-43? Why not? Mechanisms of metabolic dysfunction
in amyotrophic lateral sclerosis.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/165977/
Version: Published Version
Article:
Floare, M.-L. and Allen, S.P. (2020) Why TDP-43? Why not? Mechanisms of metabolic 
dysfunction in amyotrophic lateral sclerosis. Neuroscience Insights, 15. ISSN 2633-1055 
https://doi.org/10.1177/2633105520957302
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License  
(https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission 
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
https://doi.org/10.1177/2633105520957302
Neuroscience Insights
Volume 15: 1–19
© The Author(s) 2020
DOI: 10.1177/263310552 9 7302
Introduction
Amyotrophic lateral sclerosis (ALS) is a multi-pathogenic, 
late-onset disorder, characterized by selective loss of upper 
motor neurons in the brain, and lower motor neurons in the 
brainstem and the spinal cord.1,2 Although ALS is a fatal dis-
ease which significantly impacts on the quality of life of those 
affected, currently there is no curative treatment available and 
the present therapeutic strategies offer minimal palliative care. 
As a result, there is an urgent need for developing treatments 
that could prevent the progression of the disease and compen-
sate for its detrimental effects.
Several genetic causes have been identified as central to the 
pathogenesis of ALS, one of increasing recognition being the 
TAR DNA-binding protein 43 (TDP-43).3-7 Moreover, a 
growing body of evidence indicates that an imbalance in energy 
homeostasis is a highly prevalent aspect of ALS pathogenesis, 
which correlates closely to disease susceptibility and progres-
sion.1,8 Considering the recognition of TDP-43 as one of the 
histopathological signatures of ALS, and prevailing evidence of 
metabolic dysfunction as a ubiquitous aspect of the disease, it 
would not be conjectural to think that TDP-43 could also have 
a contribution to this deregulation of metabolic homeostasis.
In this review, we will discuss the latest findings in the field, 
highlighting the contribution of TDP-43 to mitochondrial 
defects, changes in energy-generating pathways and altered 
metabolic profiles in ALS. In addition, we will also discuss how 
the contribution of TDP-43 pathology to energy imbalance 
differs to that of other well-known genetic causes of ALS such 
as the superoxide dismutase (SOD1) gene, chromosome 9 
open reading frame 72 (C9orf72) gene and fused in sarcoma 
(FUS). We hope to provide insight into the possible molecular 
mechanisms underpinning neurodegeneration in ALS and to 
highlight potential therapeutic targets which could be explored 
by future research.
he physiological function of TDP-43 in the central 
nervous system
Transactive response DNA binding protein 43 (TDP-43) is a 
highly conserved and ubiquitously expressed member of the 
heterogeneous nuclear ribonucleoprotein (hnRNP) family, 
which plays an essential role in RNA metabolism.9 The impor-
tance of TDP-43 comes from its sequence specific-binding to 
single-stranded RNA molecules, which confers its ability to 
control cellular events such as pre-mRNA splicing and repres-
sion modulation of gene expression.3
TDP-43 is encoded by the TARDBP gene, located on chro-
mosome 1, and is composed of 414 amino acids which possess 
a complex structural organization. Even though the 3D struc-
ture of TDP-43 has not been fully characterized yet, its holistic 
structure is thought to recapitulate the classical domains of 
hnRNP proteins: an N-terminal region, two RNA recognition 
motifs (RRM1 and RRM2), and a C-terminal domain (Figure 
1a). The structural organization of the TDP-43 subunits allows 
the protein to participate in stress granule formation, and to 
interact with various binding partners in order to modulate its 
own splicing and self-organization events.3,9 Moreover, the two 
RRMs regions possess a very high affinity for UG-rich 
sequences, which enables TDP-43 to control the maturation of 
pre-mRNAs and define its splicing patterns10 (Figure 1b).
The highly specific interaction of TDP-43 with RNA mole-
cules depends on a sequence of cellular events and signaling cas-
cades which are initiated when TDP-43 comes into proximity of 
5۝ or 3۝ splice sites of long introns, untranslated regions or several 
exons. This co-localization allows the binding of TDP-43 to 
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UG-rich sequences, further signaling that the pre-messenger 
RNA requires additional processing and transport to the cyto-
plasm post-splicing. Besides splicing modulation, TDP-43 con-
trols mRNA life cycle, formation of ribonucleoprotein granules 
and regulation of non-coding RNAs.4 In addition to RNA bind-
ing, TDP-43 also binds DNA.11-17 Moreover, recent work sup-
ports the involvement of TDP-43 in the nonhomologous end 
joining (NHEJ)-mediated DNA double-strand break (DSB) 
repair pathway.18 TDP-43 rapidly interacts with NHEJ and 
DNA damage response factors to facilitate the restoration of 
chromosome breaks, whereas its experimental depletion signifi-
cantly alters NHEJ repair response and induces the accumula-
tion of genomic DNA DSBs.18 Crucially, in the context of 
neurodegeneration TDP-43 has been suggested to possess an 
elevated pathogenic potential, due to its highly dynamic and 
flexible C-terminal.3 The C-terminal region of TDP-43 has an 
intrinsically disordered organization, which makes it highly 
prone to aggregation19 and promotes toxicity.20,21 In addition, 
TDP-43’s C-terminal compartment also presents a highly 
unstable helix-turn-helix region,22,23 which, upon translation, 
can facilitate the formation of amyloid-like fibrils with prion-
like infectious properties.22,24,25 Moreover, the C-terminal frag-
ment of TDP-43 can also promote the formation of dynamic 
protein droplets, which have been suggested to play an impor-
tant role in the generation of stress granules.26
Amyotrophic lateral sclerosis, a member of the motor 
neuron disease spectrum
Motor neuron diseases (MNDs) recapitulate a group of com-
plex, neurodegenerative conditions which affect the nervous 
system, leading to progressive death of motor neurons, with 
amyotrophic lateral sclerosis (ALS) being the most common 
form (Figure 2). ALS is a late-onset neurodegenerative disor-
der, characterized by selective loss of upper motor neurons in 
the motor cortex which control bulbar muscles, and lower 
motor neurons in the spinal cord which control skeletal mus-
cles.1 This sustained neuronal deterioration leads to a series of 
motor dysfunctions such as difficulty in walking, limb weak-
ness, slurred speech, swallowing problems, impaired respiratory 
function. Death typically occurs 2 to 5 years post diagnosis.27 
Due to the fast nature of progression and low survival rate, 
ALS is regarded as a disorder of low penetrance and reduced 
incidence.2 However, this incurable condition is far from infre-
quent, with the latest data indicating a 1 in 300 to 400 lifetime 
risk factor, which continuously increases with life 
progression.28
In terms of its causation, the great majority of disease mani-
festation are considered sporadic in nature (90% of all cases). 
However, more than 35 different genes have been linked to 
ALS, with the rate of gene discovery showing a quadrennial 
twofold increase.2 Large-scale genome-wide association stud-
ies have identified four main genes as highly frequent ALS 
causative factors: the superoxide dismutase (SOD1) gene, TAR 
DNA binding protein (TARDBP) gene, chromosome 9 open 
reading frame 72 (C9orf72) gene and fused in sarcoma (FUS) 
(Figure 3).
Currently, there are limited therapeutic strategies for ALS 
patients, but alternative approaches such as antisense oligonucleo-
tides (ASOs) treatments are emerging as a viable treatment in 
SOD1-ALS cases. A recent study indicated that SOD1-ALS 
Figure 1. A. Schematic representation of the primary structural architecture of TDP-43 protein. The high functionally relevant regions are annotated (NLS 
= nuclear localization signal; NES = nuclear export signal; Q/N = core region rich in glutamate/asparagine); RRM = RNA recognition motifs. B. 
Schematic representation of TDP-43 targets, and the result of TDP-43 binding to UG-rich sequences on mRNA. After TDP-43 comes in close localization 
to the UG-rich sequences (GUGUG and UGUGU) on mRNAs, an intracellular signaling cascade indicates that the pre-messenger RNA requires additional 
processing and transport to the cytoplasm post-splicing.
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patients who received tofersen, an ASO which controls the degra-
dation of SOD1 messenger RNA, measured a dose-dependent 
reduction from baseline in the total CSF SOD1 concentration of up 
to 36% after 12 weeks of treatment.30 Even though the safety and 
efficacy of tofersen are currently under investigation, the aforemen-
tioned study provides evidence that precision-medicine approaches 
using ASO could open the way to therapeutic interventions in ALS 
and potentially other neurodegenerative conditions.
Figure 2. Schematic representation of the motor neuron disease spectrum and its accompanying symptomatology.
Figure 3. Schematic representation highlighting the genetic and environmental factors associated with ALS. ALS is a multistep process in which genetic 
mutations, rare variants and a plethora of environmental factors work together toward developing the condition, the last exposure being considered the 
disease trigger.29
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Mislocalization of TDP-43, a critical aspect of ALS 
pathogenesis
Great scientific effort has been invested into characterizing the 
pathogenesis of ALS, but many of the cellular mechanisms 
underpinning disease progression remain unclear. However, it 
is well recognized that the aggregation of hyper-phosphoryl-
ated and ubiquitinated TDP-43 protein into cytoplasmic 
inclusions represents one of the primary neuropathological 
hallmarks of ALS, supporting the contribution of TDP-43 
pathology to neurodegeneration.3,4 In a physiological state, 
TDP-43 is mainly localized in the nucleus, where it controls 
gene expression and pre-mRNA splicing, and modulates the 
regulation of its own mRNA, as discussed above. However, a 
small proportion continuously shuttles to the cytoplasm to per-
form some of its other functions, including the control of 
mRNA stability and translation.3 This dynamic character of 
TDP-43 is dependent on distinct protein import systems, and 
defects in the import/export machinery have been suggested to 
represent one of the causative steps in TDP-43 pathology3,4 
(Figure 4). Multiple hypotheses have been put forward to 
explain the underlying pathogenic mechanisms of action of 
TDP-43, leading to a debate as whether TDP-43 pathology 
stems from a loss of nuclear function, a gain of toxic cytoplas-
mic activity, or a dominant-negative mechanism.31 A context in 
which loss of function (haploinsufficiency) is the primary path-
ological modulator of TDP-43 activity would imply that the 
mutant gene has either a reduced function or no function at all, 
but does not interfere with the signaling of the wild-type allele. 
Reducing the expression of the mutant gene will reproduce the 
disease phenotype in a preclinical model, whereas overexpres-
sion of the mutant or the wild-type allele will have no patho-
logical outcome. Oppositely, in a gain-of-function scenario, the 
mutant gene may become hyperactive in one of its normal 
activities, leading to cellular toxicity. In this framework, overex-
pressing either the mutant or the wild-type form will eventu-
ally recapitulate the disease characteristics. However, it may be 
also possible for the mutant gene to acquire a novel function 
which is independent of its physiological signaling, in which 
case upregulating the mutant gene alone will trigger the dis-
ease. Finally, in a dominant-negative mechanism, the mutant 
allele possesses an inhibitory effect on the wild-type form, 
downregulating its activity. Even though it is essentially a loss 
of function, the negative effects extend toward the endogenous 
wild-type as well, differentiating it from a situation of haploin-
sufficiency. This scenario can be mimicked in an experimental 
setting by overexpressing the mutant allele, which is expected 
to consequently inhibit the endogenous wild-type protein.31 In 
the period immediately following the discovery of TDP-43 as 
a neuropathological component of ALS, studies were focused 
on gain-of-function models, providing evidence that upregula-
tion of both the mutant and the wild-type allele can cause neu-
rodegeneration (for an extensive review see32). However, with 
the progression of research, the paradigm has shifted toward an 
understanding that the aggregation of TDP-43 into cytoplas-
mic inclusions confers both a loss of nuclear activity, as well as 
a toxic gain of cytoplasmic function.33 Supporting the detri-
mental effects of TDP-43 cytoplasmic aggregates, a recent 
study performed proteomic analysis on primary cortical 
Figure 4. Schematic representation of TDP-43 cytoplasmic mislocalization, and the consequential cascade of pathological molecular events. In a 
physiological state, TDP-43 resides primarily in the nucleus, where it regulates major aspects of RNA metabolism. In a pathological context, defects in the 
structural components of the import/export machinery can facilitate the mislocalization of TDP-43 to the cytoplasmic compartment followed by its 
accumulation in cytoplasmic inclusions. The consequential abnormal signaling of TDP-43 promotes the formation of stress granules and impairs 
important pathways for cellular degradation such as autophagy.
RNA pol II, RNA polymerase II.
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neurons, patients fibroblasts and neurons derived from stem 
cells, and indicated that cytoplasmic accumulation of TDP-43 
is the result of defects in the localisation of nucleoporins and 
transport factors. This localization defect concomitantly 
impairs the nuclear pore complex, causing nucleocytoplasmic 
transport abnormalities.34 Interestingly, experiments on neu-
rons from post-mortem ALS cases that did not exhibit nuclear 
TDP-43 expression indicated that loss of TDP-43 function 
results in nucleocytoplasmic transport impairment, RNA pro-
cessing defects, DNA damage and altered histone processing.35 
Based on the previous belief that the nuclear depletion of 
TDP-43 precedes the formation of cytoplasmic inclusions,31 it 
may be possible that loss of nuclear TDP-43 contributes to 
neurodegeneration via a feedback forward mechanism in which 
cytoplasmic mislocalization and aggregation is a secondary 
insult which additionally elevates cellular toxicity. Baskaran 
et al. (2018) took this concept further when they suggested that 
TDP-43 mislocalization led to neuronal loss via a disruption of 
cytoskeletal integrity in cortical neurons, which eventually 
impaired axonal growth and microtubules dynamics.36
Nevertheless, even though extensive research has been 
focusing on the loss versus gain of function debate, valuable 
evidence proposes additional pathogenic mechanisms. For 
example, Wils et al. (2010) showed that transgenic models of 
TDP-43 developed significant neuronal cytoplasmic inclu-
sions, mainly composed of phosphorylated and ubiquitinated 
TDP-43. Yet, the prevalence of aggregates in which TDP-43 
was not the main protein deposited led to the suggestion that 
cytoplasmic accumulation of TDP-43 is not a requisite for 
TDP-43-mediated toxicity in ALS, and that TDP-43 might 
exert a destructive function by impairing protein degradation 
pathways.37 This hypothesis is in line with previous research 
highlighting the contribution of TDP-43 to modulating 
autophagy, a crucial self-degradation process of cleaning out 
defective cells and organelles to allow the regeneration of 
newer, healthier cellular components.38 In this context, it may 
be possible that abnormalities in the physiological functioning 
of TDP-43 lead to downstream defects in the autophagy path-
way, initiating a positive feedback loop which enhances the 
aggregation of cytoplasmic inclusions (Figure 4). Indeed, 
genetic engineering of autophagy modulators such as Atg5 or 
Atg8 initiated neuronal defects and resulted in neurodegenera-
tion,39 whereas more recent studies revealed that mutations in 
several genes responsible for autophagy could be classified as 
etiological factors for ALS regulation.40 Interestingly though, 
pharmacological manipulation of autophagy resulted in con-
flicting results,41,42 where factors such as differences in meth-
odologies, the nature of the drug tested or the disease stage at 
which the drug administration began lead to significant 
variability.
When discussing the possible contribution of TDP-43 to 
neuronal toxicity, it is important to note its involvement in the 
formation of stress granules (SGs). As mentioned above, low 
levels of TDP-43 are continuously shuttled to the cytoplasmic 
compartment to control mRNA stability. At this level, when 
exposed to various environmental stressors such as viral infec-
tions, heat shocks, osmotic or oxidative agents, TDP-43 can be 
recruited to cytoplasmic RNA granules called stress granules. 
These stress granules are membrane-less organelles which cap-
ture non-essential mRNAs, RNA-binding proteins or transla-
tion factors, and hinder the translation of mRNA targets to 
ensure cell survival and to protect them against degradation 
due to cellular insults.43,44 This property is conferred by the 
C-terminus head of the TDP-43 protein, which enables liq-
uid-liquid phase separation (LLPS) activity. Normally, the pro-
cess of SG formation is reversible and SGs get immediately 
absorbed after the stress has passed. However, certain ALS-
related TDP-43 mutations have been suggested to act on the 
LLPS properties, impairing SG dynamics and facilitating the 
accumulation of TDP-43 inclusions (Figure 4).4,44
The studies discussed in the section above provide evidence 
for the contribution of TDP-43 dysfunction to ALS patho-
genesis, arguing that TDP-43 pathology reflects a complex 
interplay between loss and gain of function mechanisms which 
alters neuronal health and eventually promotes cell death. 
However, with the contemporary research in mind, the ques-
tion of whether the cytoplasmic mislocalization and accumula-
tion of TDP-43 are a cause or a consequence of ALS remains 
to be addressed in future studies for a comprehensive, in depth 
understanding of disease etiology and progression.
he pathogenic contribution of fused in sarcoma 
protein to ALS
Fused in sarcoma is another member of the RNA binding pro-
teins group, whose physiology and cellular activity show great 
synonymy to those of TDP-43, both in a healthy and a dis-
eased state.45 Similar to TDP-43, FUS’ primary localization is 
within the nucleus, and its physiological activity has implica-
tions on different features of RNA metabolism, including tran-
scription and splicing regulation,46,47 mRNA transport48,49 and 
DNA damage repair.50,51 Moreover, a percentage of the protein 
is present in the cytoplasm and the neuronal processes, where it 
carries out functions associated with mRNA transport and 
local protein translation.52 Considering the dynamic nature of 
the protein, defects in the nuclear import machinery could 
have a detrimental effect on both the nuclear function and the 
cytoplasmic activity. Indeed, retention of FUS in the cyto-
plasm, followed by its accumulation in cytoplasmic inclusion, is 
a well-recognized pathological feature of ALS.53 However, as 
for TDP-43, there is a continuous debate around the contribu-
tion of the associated reduction in nuclear expression or cyto-
plasmic gain of toxic function to motor neuron death in ALS 
pathogenesis. As nuclear FUS plays a crucial role in modulat-
ing RNA metabolism, mutations associated with its coding 
gene could hinder genetic expression and impair alternative 
splicing events, leading to transcriptome deterioration as sug-
gested by FUS knock-out models.45 However, complete inacti-
vation of FUS resulted in post-natal mouse death, making it 
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difficult to identify any neuro-related phenotypes.54 A more 
substantiated hypothesis proposes cytoplasmic mislocalization 
and gain of toxic attributes as the initial steps in the disease 
cascade, arguing that reduced nuclear activity does not directly 
contribute to motor neuron degeneration in ALS.55 
Experimental efforts have been made to compare the patho-
logical phenotype of models expressing mutant cytoplasmic 
FUS against those with complete ablation of FUS protein. The 
results showed perinatal loss of motor neurons in the knock-in 
group, but not in the knockout cohort, and are substantiated by 
the observation that rescue of nuclear FUS arrested motor 
neuron death.55 Moreover, the accumulation of FUS cytoplas-
mic inclusions has been associated with the formation of SGs,56 
whose pathological traits have been discussed in the context of 
TDP-43 pathology in the section above. Considering the evi-
dence discussed so far, even though the mechanisms through 
which FUS contributes to neurodegeneration remain an open 
question, impairments in FUS functionality is an undisputed 
feature of ALS pathology and its pathogenicity cannot be 
contested.
Superoxide dismutase 1 enzyme pathology in ALS
Pathological expression of SOD1 enzyme has been described 
as the first genetic cause of ALS, being responsible for one fifth 
of familial disease cases.57 SOD1 is a highly conserved and 
ubiquitously expressed protein, typically localized to the cyto-
plasm and more sparsely in the nucleus, lysosomes and mito-
chondrial intermembrane space.58 As a requisite cytoplasmic 
antioxidant, SOD1’s primary function is to catalyze the con-
version of highly toxic superoxide radicals (oxygen molecules 
which possess an additional electron) into molecular oxygen 
and hydrogen peroxide, providing, as a result, a defence mecha-
nism against ROS-driven stress.59 However, SOD1 activity 
extends to other roles independent of its dismutase-like char-
acter, including respiration repression and energy metabolism 
regulation,60 protein nitration,61 copper buffering,62 immu-
nomodulation,63 zinc homeostasis,64 and phosphate activa-
tion.65 Initially, SOD1 pathology was linked to 
neurodegeneration in ALS via a loss of physiological function 
and a consequent accumulation of toxic superoxide radicals. 
However, subsequent research on transgenic models of ALS 
overexpressing both the endogenous mouse gene, as well as the 
mutant human SOD1, contradicted the incipient theories, 
showing that the majority of these disease models exhibit 
enhanced dismutase activity and progress into adult-onset 
motor deficits with distinctive loss of lower motor neurons.66 
As a result, a new hypothesis was put forward, arguing that 
SOD1 pathology is not associated with a reduced dismutase 
activity, but with the acquisition of one or more toxic properties 
of the mutant protein.67 In this context, SOD1 has been sug-
gested to contribute to neuronal death by impairing the expres-
sion of the glutamate transporter EAAT2, leading, as a result, 
to accumulation of glutamate at the level of the synaptic cleft 
and consequent glutamate excitotoxicity.68 This proposed 
mechanism was supported by evidence from SOD1 mutant 
mice, which exhibited a 50% reduction in the level of EAAT2 
protein in the spinal cord,69 and a further complete depletion in 
EAAT2 concentration by the end-stage of the disease.70 
Moreover, EAAT2 expression was reported to be decreased or 
abnormal in ALS patients as well,71 further confirming SOD1 
pathogenicity and its contribution to disease progression. 
Defects in axonal organization and disrupted transport have 
been suggested to be another effect of SOD1 toxicity that 
could potentially lead to motor neurons death in ALS.72 
Moreover, by interfering with the axonal transport machinery, 
SOD1 toxicity may indirectly impair the distribution of mito-
chondria to the periphery or impede retrograde delivery of 
trophic factors.73
The findings discussed above are a few of the proposed 
mechanisms through which SOD1 gain of toxic function could 
progress to neurodegeneration, complementing the suggestion 
that loss of dismutase activity is not the driving factor of SOD1 
pathology in ALS. Moreover, recent research showed that 
SOD1 translocates to the nuclear compartment in a sub-group 
of sporadic ALS patients, and suggested a potential protective 
function at this cellular level.74 The possibility that, once relo-
cated to the nucleus, SOD1 may act as a co-transcriptional fac-
tor of DNA repair genes to reduce genomic damage was 
proposed by experiments which correlated the presence of 
nuclear SOD1 with significantly increased disease 
duration.74Therefore, in the light of the evidence discussed 
above, it could be argued that loss of SOD1 dismutase activity 
possesses a modifying role in ALS pathogenesis, and its poten-
tial protective nuclear function could open the way to notable 
therapeutic strategies.
C9orf72-mediated pathology in ALS
Understanding the etiopathogenesis of ALS increased signifi-
cantly in 2011, when the discovery of a hexanucleotide repeat 
expansion GGGGCC in the C9orf72 gene was attributed to as 
much as 33% of all familial cases of ALS and 5% of idiopathic 
disease forms.75 In a non-pathogenic state, the C9orf72 gene 
incorporates 5 to 30 hexanucleotide repeats, showing a neuro-
logically healthy phenotype.76 As a result, an arbitrary 
30-repeats cut-off has been suggested to mark the threshold 
beyond which the repeat length becomes pathogenic, and 
expansions of hundreds to thousands of repeats are a highly 
common genetic feature of C9orf72-ALS (C9-ALS) patients.77 
However, repeat lengths of 30 or more have also been reported 
in 0.17% of healthy individuals, indicating that the knowledge 
of the repeat cut-off must be cautiously used both clinically 
and experimentally.76
The physiological function of the C9orf72 gene in the CNS 
is still poorly understood, being mostly substantiated by experi-
ments investigating its pathogenic activity. The non-coding 
expanded repeats have been shown to contribute to C9orf72 
gene silencing in blood samples from C9-ALS patients,78 lead-
ing to a consequential reduction by almost 50% in the C9orf72 
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mRNA and protein levels.79 As a result, loss of function mech-
anisms has been proposed as a pathogenic contribution of 
C9orf72 protein to ALS etiology.80 So far, bioinformatic analy-
sis has revealed a protein coding domain in the C9orf72 gene, 
which shows a direct interaction with the Rab family of GTP-
ases.81 As Rab proteins are active regulators of many mem-
brane trafficking steps across a wide range of cell types, C9orf72 
loss of function may have downstream effects on protein trans-
port mechanisms. Interestingly, both TDP-43 pathology and 
TDP-43-negative but ubiquitin-positive inclusions have been 
often reported in C9-ALS patients, further indicating defects 
in transmembrane transport and protein degradation in carri-
ers of C9orf72 repeat expansions.82
Interestingly, the possibility that the G4C2 repeat expan-
sions might be pathogenic through a gain of toxic activity 
emerged when experiments showed that the hexanucleotide 
extensions can be transcribed into repetitive RNAs in a bidi-
rectional fashion, leading to the formation of nuclear RNA 
foci.83 Even though these repetitive RNAs are located in a 
noncoding region of the C9orf72 gene, they can be translated 
to five different and highly toxic dipeptide repeat proteins 
(DRPs).83 As a result, two scenarios have been put forward, 
indicating that the expanded repeats could cause neuronal 
damage either through a toxic gain of function from the RNA 
repeats, or a destructive signaling of the DRPs.76,77 In vivo 
experiments suggested that the RNA repeat foci co-localize 
with TDP-43 and FUS, facilitating their sequestration and 
contribution to dysfunctional RNA-metabolism mecha-
nisms.84 Moreover, the G-rich repeats have been suggested to 
assemble into helical G-quadruplex secondary structure, deter-
mining abnormal cellular activity and interactions with other 
proteins.85 In line with these findings, Walker et  al. (2017) 
showed that both RNA-repeat expansions and poly-GA DPRs 
contribute to the formation of DNA-RNA hybrids called 
R-loops in C9orf72 rat neurons, human cells, as well as in spi-
nal cord tissue from C9-ALS patients. The resultant disrup-
tion of ATM-mediated DNA repair signaling and 
accompanying accumulation of DNA breaks appeared to be 
the result of C9orf72-mediated p62 aggregation.86 Furthermore, 
numerous previous studies in cell lines and mouse models sug-
gested that the expression of each individual DRP may be suf-
ficient to cause neurodegeneration through induced 
nucleocytoplasmic transport defects,87 abnormal proteasomal 
degradation and protein sequestration,88 nucleolar stress89 or 
protein translation inhibition.90 Nevertheless, these pre-clini-
cal studies recapitulate an overexpressed DRP pathology, aspect 
that makes it difficult to correlate the results with the endoge-
nous patterns noticed in patients, and which emphasizes the 
crucial need for more clinical and experimental work.
However, despite the lack of knowledge around the specific 
molecular pathways downstream to loss of functional C9orf72, 
or gain of toxic C9orf72 driven activity, both mechanisms are, 
presumably, contributing to ALS pathogenesis to some extent, 
and the evidence discussed above supports the existence of 
complex and profound implications of C9orf72 pathology on 
cellular homeostasis and neuronal integrity.
ALS, a multi-systematic disorder: implications for 
metabolic dysfunction
An increasingly recognized aspect of ALS pathology is repre-
sented by a disturbance in energy balance, which, in the last 
decades, has changed the experimental approach toward ALS 
pathogenesis and led to revolutionary insights into disease 
mechanisms. It appears that ALS patients often report a 
decrease in energy uptake, which, controversially, is accompa-
nied by an increase in energy expenditure, along with lower 
body mass index (BMI) in the pre-symptomatic phase of the 
disease and hypolipidemia at later disease stages.1 These 
changes lead to a state of hypermetabolism, that is considered 
to be the result of increased respiratory muscle expenditure, 
and which seems to correlate closely with disease susceptibility 
and progression. Moreover, this apparently abnormal metabolic 
condition is correlated with accentuated cognitive impairment 
and significantly reduced survival rate.8 Two recent clinical 
studies suggested that the risk for ALS was accurately pre-
dicted by the reduction in BMI, whereas high fat mass levels 
prolonged survival.91 However, it is important to note the limi-
tations of case-control studies, whose methodology is based on 
questionnaires regarding the dietary habits of patients before 
the onset of the clinical manifestations, making such experi-
ments prone to recall bias.
In line with the protective association between vascular risk 
factors such as high BMI,92 hyperlipidaemia93 or increased cho-
lesterol levels94 and ALS survival,95 diabetes appears to be 
another chronic metabolic disorder involved in ALS etiology. 
Recent Danish and Swedish large case-control studies sug-
gested a 0.61 to 0.66 odds ratio of diabetes in ALS patients 
pre-diagnosis, with age related alterations found indicating a 
protective associations with type 2 but not type 1 diabetes.96,97 
On average, patients with type 2 diabetes report abnormal 
energy metabolism with increased levels of lipids in the blood 
and elevated BMI,98 aspects that could explain a possible posi-
tive effect of diabetes on ALS. However, even though there is a 
clear crosstalk between insulin signaling and the underlying 
mechanisms of ALS,1 the direction of this association still needs 
to be elucidated as, so far, the experimental results are rather 
contradictory and inconsistent. Recent studies investigating 
systematic metabolic dysfunction in ALS suggested a protective 
effect of diabetes in patients aged 65 and above, while the 
younger groups appeared to be at higher risk.96,97 Interestingly, 
a recent Italian nested longitudinal study found a negative cor-
relation between diabetes and ALS in older individuals,99 while 
previous research in an Asian population suggesting elevated 
ALS risks in the elderly.100 No gender correlations have been 
distinguished in a Taiwan-based study,100 contradicting the 
results of two other East Asian-nested studies which showed 
that men with type II diabetes recorded an increased risk of 
developing ALS compared to women of the same race.101,102
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The contribution of metabolic dysfunction to ALS-
associated neurodegeneration is further supported by evidence 
from dietary intervention experiments, which indicate that 
elevated glucose or serum lipids levels could compensate for 
the hypermetabolic syndrome reported in ALS patients.99 The 
risk of developing ALS appeared to be reduced in both animal 
models and humans following a diet rich in both vegetal and 
marine Z-3 polyunsaturated fatty acids (PUFAs).103 As PUFAs 
are known to reduce the expression of nuclear factor NB, a 
higher PUFAs intake may be helpful in reducing inflamma-
tion, oxidative stress and glutamate-mediated toxicity, contrib-
uting therefore to neuronal survival.104-107 Moreover, in obesity 
and type 2 diabetes, the levels of an important neurotrophic 
and neuroprotective protein, progranulin, are known to be ele-
vated108,109 and previous research showed that progranulin can 
also work against the toxic effects of TDP-43.108
Nevertheless, despite the high incidence of ALS and 
impaired insulin signaling, the underlying mechanisms of this 
associated need to be further investigated in detail. Nevertheless, 
the imbalance in energy metabolism remains an undeniable 
characteristic of ALS pathology, and understanding how these 
systemic metabolic defects are causally connected to motor 
neurons loss could provide great insight into disease pathogen-
esis and possible therapeutic strategies.
Mitochondria pathology, a major driver of metabolic 
dysfunction in ALS
Mitochondria are a major player in ATP production and lipid 
homeostasis. Impaired activity of the electron transport chain 
(ETC), disruption in mitochondrial fusion/fission rates, abnor-
mal morphological changes or calcium buffering defects, can 
lead to reduced ATP production and dysfunctional glucose and 
lipid metabolism.110 Compelling evidence shows that the func-
tion of each component of the electron transport chain is 
altered in sporadic ALS patients111 and even though each 
genetic cause contributes in a variant-specific manner to mito-
chondrial pathology, there seems to be a certain degree of over-
lap in terms of which aspect of mitochondrial function or 
structural component is compromised.
In this context, the specific interaction between different 
ALS-associated proteins and the mitochondria appears to be 
crucial to the infliction of mitochondrial damage in ALS 
pathogenesis.112 For example, mutant TDP-43 has been sug-
gested to possess an internal mitochondrial targeting sequence, 
which facilitates a preferential binding to the mRNAs of the 
mtDNA-encoded complex 1 subunits ND3 and ND6, imped-
ing their transcription and leading to consequential reduced 
expression of complex I.113 As part of the complex mechanisms 
of oxidative phosphorylation, ROS is a physiological by-prod-
uct which, at homeostatic levels, acts as a signaling molecule. 
However, abnormal functioning of the ETC can result in an 
excessive ROS production and consequently promote damage 
to the mtDNA, RNA, proteins and lipids.114 Elevated levels of 
ROS markers and pronounced ROS-associated damage have 
been extensively reported in sporadic ALS patients,115 as well 
as in transgenic or cellular models of ALS upregulating either 
TDP-43116 or FUS synthesis.117 Moreover, recent studies show 
that both TDP-43 and FUS pathologies alter the ability of 
mitochondria to maintain inner membrane integrity and dis-
rupt mitochondria-endoplasmic reticulum (ER) signaling by 
impairing the binding of the endothelial vesicle-associated 
membrane protein associated-protein B (VAPB) to the mito-
chondrial associated protein tyrosine phosphatase interacting 
protein 51 (PTPIP51).118 Defects in ER-mitochondria com-
munication may further impair the Ca2+ exchange system 
between the two organelles, reducing calcium uptake and 
potentially contributing to a series of additional toxic mecha-
nisms, including loss of protein homeostasis and axonal trans-
port defects.119
Interestingly, a sequestration pathological mechanism has 
been proposed in transgenic models of SOD1 as well, as mutant 
SOD1 builds up in the intermembrane space and forms aggre-
gates which impair the activity of the ETC, especially com-
plexes I and IV.120,121 Moreover, previous research on SOD1 
models described decreased calcium homeostasis122 and an 
abnormal interaction between mitochondria and the ER,123 
but a causal link between these two features of ALS pathology 
is still to be confirmed in SOD1 mutants. Elevated level of 
ROS have been reported in SOD1 models as well,124 and 
TDP-43, FUS and SOD1 themselves have been suggested to 
be a target of oxidative damage, which promotes their aggrega-
tion and possibly facilitates the progression of pathological cas-
cades through a damaging positive feed-forward loop.125
Consistent with the contribution of TDP-43 to impaired 
calcium homeostasis, abnormal mitochondrial morphology 
accompanied by its accumulation in motor axons has been pre-
viously reported in mice models overexpressing wild-type 
TDP-43, but not in mutant cohorts.126 These contradictory 
results may account for different pathological mechanisms 
between wild-type and mutant TDP-43 forms, which will be 
discussed in detail in the section below. Similarly, mitochon-
drial clustering was reported in transgenic SOD1 models as 
well,127 when Vande Velde et al. (2008) demonstrated that mis-
folded SOD1 creates very tight associations with the outer 
mitochondrial membrane in mutant SOD1 models,128 possibly 
altering its motility along with others physiological proper-
ties.129 However, the association of SOD1 with the mitochon-
dria was restricted to the spinal cord, suggesting a potential 
site-specific pathogenic activity.
Considering the high incidence of TDP-43 aggregation in 
cases of GGGGCC expanded repeats, one could readily spec-
ulate that mitochondrial morphology and its ATP synthase 
machinery are a target of C9orf72 pathology as well. 
Accordingly, experiments on iPSC-derived C9orf72 motor 
neurons reported increased DNA damage compared to con-
trols, and a preferential binding of DRPs, especially poly(GR), 
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to mitochondrial ribosomal proteins. This toxic effect of 
DRPs compromised mitochondrial function and led to ele-
vated levels of oxidative stress in an age-dependent manner, 
possibly explaining the presence of DNA damage.130 However, 
as mentioned in one of the previous sections, the results of 
such studies are usually harder to interpret and integrate 
within the current knowledge, as they express high levels of 
poly(GR), much greater than those recorded in ALS patients. 
To overcome this limitation and approximate more to the 
physiological conditions, Choi et  al. (2019) developed an 
inducible mouse model of C9orf72-dependent toxicity in 
which the levels of (GR)80 accumulate in a progressive, con-
trolled manner in cortical motor neurons.131 The mice showed 
significant defects in mitochondrial function and morphol-
ogy from as early as 3 months of age, before any other cogni-
tive or cellular impairments, arguing that mitochondrial 
dysfunction is a prodromal event in the ALS disease course, 
and that lower pathogenic levels of diffusible poly(GR) are 
sufficient to initiate the disease. The poly(GR) showed affin-
ity for ATP5A1 subunit of the mitochondrial ATP synthase, 
increasing its degradation via the ubiquitin-proteasome path-
way and consequently impairing mitochondrial ATP produc-
tion. As the disease progresses, a full spectrum of ALS 
pathological characteristics including synaptic dysfunction, 
neuronal loss, cognitive impairment, microgliosis and DNA 
damage was measured, which possibly developed as a conse-
quence of impaired mitochondrial activity and energy bal-
ance. Interestingly, TDP-43 pathology appeared to be absent 
in the transgenic cohort, possibly indicating that poly(GR) 
toxicity is the initiating factor in C9-ALS, and that TDP-43 
pathology follows later in the disease pathogenesis, poten-
tially as a consequence of altered protein transport mecha-
nisms and impaired autophagy.78 Since recent evidence 
reinforces the hypothesis that mutant forms of TDP-43 
themselves interact with and impair the assembly and func-
tion of the oxidative phosphorylation system, causing toxicity 
and mitochondrial damage132,133 we speculate that TDP-43 
may function differently on its own, compared to when it is 
associated with C9orf72 pathology. Contrarily, it may also be 
possible that cascades upstream to TDP-43 inclusions are 
facilitating the progression of neurodegeneration in C9ALS 
cases, and that TDP-43 aggregation itself is a consequence, 
rather than a cause of the disease.
Taken together, the studies discussed above support the 
existence of metabolic dysfunction in ALS, providing evidence 
for the crucial contribution of mitochondria pathology to ALS 
pathogenesis (Figure 5). However, even though it is increas-
ingly apparent that multiple aspects of mitochondria morphol-
ogy and physiology are damaged in ALS, there are still many 
gaps in our knowledge regarding the molecular pathways 
involved, gaps that must be filled before shifting our focus 
toward finding therapeutic strategies against motor neuron 
degeneration.
he potential contribution of glycolysis and fatty acid 
oxidation to restoring energy balance
When discussing energy metabolism and mitochondrial 
pathology, it is worth taking a step backwards in the pathways 
of cellular respiration and look more attentively into the pos-
sible implications of glycolytic flux and fatty acid oxidation 
(FAO) on ATP production. Glycolysis is a crucial energy gen-
erating process and, at the same time, a vital step for aerobic 
cellular metabolism which, in its energy-releasing phase, pro-
vides the substrates required for oxidative phosphorylation. 
The general consensus promotes glucose as the principal sub-
strate which satisfies energy requirements in the brain, arguing 
that, although others organs with increased energy turnover 
such as the kidney or the heart largely rely on fatty acids oxida-
tion for energy supply, the brain has a preference toward glyco-
lytic rather than oxidative metabolism.134,135. The low rate of 
fatty acid oxidation in the brain might be explained in part by 
the relatively low permeability of the blood-brain barrier to 
fatty acids, the higher oxygen demand and superoxide genera-
tion for FAO compared to glycolysis, along with the decreased 
enzymatic capacity for fatty acid degradation.134. However, 
increasing attention has been drawn to lipid metabolism in the 
central nervous system, since previous studies have suggested 
that oxidation of fatty acids contributes almost 20% to the total 
brain’s energy demands,136 and caloric-dense diets can improve 
disease outcomes.95 In the light of the current discoveries, there 
seems to be an exquisite interplay between glycolysis, fatty acid 
oxidation and oxidative phosphorylation in the brain, and the 
ability to metabolically switch between these energy-transduc-
ing pathways may be crucial in terms of securing the much 
needed constant energy support to neuronal cells.137 In this 
context, a recent elegant study on a Drosophila model of TDP-
43-ALS reported the upregulation of key genes involved in 
glucose metabolism,138 reiterating at the same time the contri-
bution of TDP-43 to mitochondrial dysfunction. The results 
indicate that, as ALS progresses, glycolysis might be upregu-
lated in dying motor neurons as a compensatory mechanism 
for the loss of mitochondrial ATP, and could even confer neu-
roprotection by increasing the levels of pyruvate levels, a physi-
ological metabolic intermediate and antioxidant which has 
been shown to safeguard mitochondria against oxidative 
stress.139 Interestingly, despite the great pathogenic similarity 
between TDP-43 and FUS and the extensive circumstantial 
evidence linking both DNA binding proteins to impaired 
energy metabolism, mutations in FUS appeared to have no 
effect on glycolytic or mitochondrial energy metabolism in a 
recent study on iPSC-derived MNs from FUS-linked ALS 
patients.140
Previous work from our laboratory showed that fibroblasts 
from mutant-SOD1-I113T ALS patients undergo a similar 
switch in energy generating pathways to that observed in the 
TDP-43 model.141 Our results reported mitochondrial defects 
and reduced ATP production from oxidative phosphorylation, 
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which, however, was accompanied by an increase in glycolytic 
flux. It seemed that mSOD1 fibroblasts were in a “fasted-like-
state” with limited FAO fueled respiratory flux compared to 
controls, either as a pathogenic consequence of the SOD1 
mutation, or a physiological consequence of upregulated glyco-
lysis. Similar “starvation” phenotypes have been previously 
reported in both SOD1 and TDP-43 transgenic models and 
correspond closely to the hypolipidemic state previously 
observed in ALS patients.142 This parallel upregulation of 
glycolysis might be either a compensatory response to the loss 
of mitochondrial ATP synthesis, or, on the contrary, an effect 
of the TDP-43 and SOD1 mutations which further drives 
mitochondrial uncoupling and limits ATP production via the 
ETC. A possible explanation to account for these metabolic 
modifications could implicate the canonical WNT/E-catenin 
pathway, an apparently crucial factor in the progression and 
development of many neurodegenerative diseases.143 Previous 
research reported upregulation of WNT/E-catenin signaling in 
Figure 5. Schematic representation of mitochondrial pathology in ALS. Defects in mitochondrial morphology and physiology can impair the activity of the 
electron transport chain (ETC), lead to accumulation of reactive oxygen species (ROS) and promote calcium buffering defects. Table summarizing the 
effects of the main genetic causes of ALS and of the sporadic form on different aspects of mitochondrial structure and functioning.
Co Q, coenzyme Q; Cyt c, cytochrome c; ER, endoplasmic reticulum; IMM, inner mitochondrial membrane; MMP, mitochondrial membrane potential; mtDNA, 
mitochondrial DNA.
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the motor neurons of SOD-1-ALS transgenic models,144 
which, in return, may activate pyruvate dehydrogenase kinase-1 
and consequently hinder the conversion of pyruvate into acetyl-
CoA and hampers its entry into the tricarboxylic acid (TCA) 
cycle. Overexpression of WNT/E-catenin pathway also acti-
vates monocarboxylate lactate transporter-1, which facilitates 
the transport of lactate into the extracellular environment.145 
Moreover, upregulating the activity of the peroxisome prolifer-
ator-activated receptor gamma (PPAR gamma), a repressor of 
the beta-catenin pathway, exerted neuroprotective effects in 
TDP-43 and FUS Drosophila models of ALS.146 This possible 
association between the WNT/E-catenin signaling pathway 
and metabolic changes is supported by evidence from experi-
ments on the NSC-34 cell line, in which expression of mutant 
SOD1G93A led to increased aerobic glycolysis as a conse-
quence of pyruvate dehydrogenase kinase 1 activation.147 
However, in the NSC-34 study, the increase in glucose metab-
olism impaired the ability of the cells to adapt to stress and 
promoted cellular death, making it difficult to conclude 
whether the increase in glycolytic flux is neuroprotective or has 
detrimental effects on motor neurons. In line with the effects of 
SOD1 on FAO observed in our laboratory, recent experiments 
in a TDP-43 Drosophila model of ALS revealed that TDP-43 
pathology alters the transcription of crucial components of the 
carnitine shuttle, leading to a significant reduction in lipid beta 
oxidation.148 Although it is unclear what underlines this dis-
tinctive malign activity of TDP-43, dietary supplementation 
with medium-chain fatty acids, which independently cross the 
mitochondrial membrane, mitigated the carnitine deficit and 
rescued motor neuron survival.
Contradicting the evidence that glycolysis might increase in 
ALS in an attempt to counterbalance the loss of mitochondrial 
contribution to energy production, gene expression profiling in 
fibroblasts from sALS suggested a dysregulation of glycolysis 
and mitochondrial oxygen consumption in the pathogenesis of 
the disease, as a result of reduced expression of insulin signaling 
receptors and of key enzymes of the TCA cycle.149 The authors 
propose that, as glucose oxidation decreases and mitochondrial 
defects progress, cells switch the energy substrate to fatty acids, 
a possibility supported by the upregulation of genes responsible 
for fatty acid transport and oxidation as shown by microarray 
analysis. Moreover, Szelechowski (2018) suggest that both gly-
colysis and FAO are decreased in fibroblasts from SOD1-ALS 
patients, whereas SOD1G93A motor neurons report increased 
activity in these two energy-producing pathways, with a larger 
preference for FAO.150 The study supports the existence of 
tissue-specific alterations in ALS pathophysiology and sug-
gests that changes in mitochondrial morphology and mito-
chondrial bioenergetics accommodate a metabolic switch from 
glucose toward FAO and ketogenesis. This hypothesis is sup-
ported by dietary intervention studies which highlighted the 
positive effects on disease onset and survival of high fat diets in 
TDP-43 and SOD1 mice,151 as well as ALS patients.95,152 To 
possibly explain the metabolic preference for FAO in the con-
text of SOD1 pathology, Szelechowski (2018) highlights pre-
vious findings which show that abnormal SOD1 binds to the 
mitochondrial outer membrane and inhibits conductance 
through voltage dependent anion channels (VDACs), thereby 
leading to bioenergetic blockade.153 Considering that fatty 
acids have the ability to diffuse through the mitochondrial 
membrane, FAO could represent a more sustainable energy-
transducing pathway which by-passes this energetic impair-
ment. However, even though previous studies have shown that 
TDP-43 interacts with VDACs as well, influencing the mito-
chondrial dynamics,154 it is still unknown whether it leads to 
similar downstream changes as seen in SOD1 cases, and a 
comprehensive characterization of the context in which these 
metabolic changes occur is yet to be put forward.
When discussing energy balance in the nervous system, it is 
important to note that neurons do not function as isolated 
units, and their unique energy capacity makes them dependa-
ble on surrounding cells like astrocytes and oligodendrocytes 
for metabolic support. 134,155 During intense synaptic activity 
astrocytes take up glucose and metabolize it into pyruvate, 
which gets further converted to lactate. It has been postulated 
that lactate is then delivered to neurons via the astrocyte-neu-
ron lactate shuttle, where it is converted back to pyruvate and 
enters the TCA cycle to feed into oxidative phosphorylation.156 
It is well established now that ALS has a non-cell-autonomous 
character where astrocytes are a particularly important target of 
disease pathogenicity.157 Any impairments in metabolic path-
ways within astrocytes or reductions in their ability to opti-
mally deliver the necessary substrates to neurons could 
profoundly affect neuronal homeostasis and contribute to neu-
rotoxicity and cell death. In line with this, the monocarboxylate 
transporter 1 (MCT1), an important modulator of lactate 
transport, has been shown to be downregulated in TDP-43 
astrocytes cultures158 and in spinal cord oligodendrocytes from 
SOD1 transgenic mice,159 whereas MCT4 measured decreased 
expression in SOD1 astroglia.159 In their recent study, Velebit 
et  al. (2020) suggest that astrocytes which exhibit TDP-43 
inclusions suffer alteration in aerobic glycolysis and accumula-
tion of lipid droplets, which consequently perturb astroglia 
metabolism and impair the trophic support of neurons.158 
Moreover, we have recently reported an altered metabolic pro-
file in induced astrocytes from C9ALS patients, where defects 
in nucleoside, glycogen, pyruvate and fructose metabolism cor-
responded to a decrease in metabolic flexibility.137,160 It appears 
that C9orf72 induced astrocytes have a decreased capacity to 
mobilize glycogen, an aspect that could reduce glucose levels 
and consequently minimize ATP production in times of bioen-
ergetic stress.137
Even though the aforementioned studies investigate two 
separate metabolic pathways, FAO and glycolysis, in geneti-
cally distinct models of ALS, their findings emphasize the cru-
cial role of metabolic flexibility in ALS, and capture the attempt 
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of the cells to mitigate metabolic stress in order to restore 
energy homeostasis. Both pathways have the capacity to modu-
late the activity of the other, but considering the complex 
downstream signaling cascades influenced by these major 
energy generating-systems, it remains an open question 
whether increasing the activity in one to the detriment of the 
other is beneficial in the long term or not (Figure 6). The pos-
sible increase in FAO discussed above could potentially further 
facilitate the inhibition of glucose oxidation, leading to glucose 
intolerance and insulin resistance, as previously reported in 
ALS patients.161 Moreover, patients with ALS often report 
dysphagia and a consequential reduction in food intake,162 
which, coupled with a possible dependence on FAO to meet 
the energy needs, may eventually lead to a depletion of fat 
stores. Indeed, a decline in BMI and loss of body weight is a 
common aspect in ALS patients, which correlates with a more 
rapid progression of the disease.163 On the other hand, increas-
ing glycolysis in cortical neurons could reduce the flux of glu-
cose through the pentose phosphate pathway, consequentially 
diminishing the antioxidative contribution of NADPH (Figure 
6). Nevertheless, it is also very important to note that the high 
variability of the findings discussed in the section above, and by 
extrapolation, in the neuroscience literature at large, must be 
considered in the context of research methodologies and trans-
lational limitations. In a preclinical context, the biological pro-
cess of interest is manipulated by a scientist in an animal model 
before the results are correlated with data from clinical studies. 
This approach allows for variability and the possibility of errors 
being introduced as each methodological step. Such limitations 
must be considered when analysis and integrating novel find-
ings with the preexisting dogma.
It is still soon to conclude what exactly are the shifts in met-
abolic pathways that ALS may trigger, and to declare with cer-
tainty whether they are beneficial compensatory mechanisms 
or a result of ALS-associated mutagenesis. However, it is indis-
putably clear that neurons and glial cells are trying to respond 
to the metabolic defects accompanying disease progression, 
and future research is needed to devote to understanding these 
responses as they could represent potential targets for thera-
peutic strategies.
Figure 6. Graphic representation of the possible effects of upregulating glycolysis or fatty acid oxidation, and their correlation with clinical data (upper 
igure). Table summarizing the indings of the aforementioned studies on the contribution of glycolysis and fatty acid oxidation to restoring metabolic 
homeostasis (lower table).
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Where does AMPK signaling sit in the context of 
TDP43-ALS pathogenesis?
AMP-activated protein kinase (AMPK) is a master regulator 
of energy homeostasis which is gaining increasing attention in 
the context of metabolic dysfunction in ALS. AMPK signaling 
is a crucial factor in detecting the balance between energy sup-
ply and demand, having a pivotal role in many intracellular 
regulatory pathways that range from energy metabolism to cel-
lular stress.164 In a pathological state, the AMPK pathway is 
activated to reduce energy expenditure and to facilitate glucose 
utilization when ATP levels become critical, either due to its 
production being compromised or its degradation being abnor-
mally enhanced.164 Considering that energy homeostasis 
becomes impaired in ALS, due to abnormal activity in any of 
the energy-generating pathways discussed above, AMPK sign-
aling might also be consequently impeded and may contribute 
to disease pathogenesis. Indeed, recent studies suggest that 
AMPK cellular activity is dysregulated in the context of ALS 
pathology, but evidence to support the signaling mechanisms 
involved is unfortunately insufficient and limited to TDP-43 
and SOD1 pathologies.
Previous research has shown that upregulation of the 
AMPK pathway facilitates the mislocalization of TDP-43 in 
NSC-34 cells via a positive feedback mechanism in which 
TDP-43 plays the central role.165 It appears that cellular stress 
and elevated levels of ROS activate the AMPK pathway, which, 
possibly due to its role in nucleocytoplasmic transport,166 
mediates the mislocalization of TDP-43. In turn, TDP-43 
contributes to additional cellular oxidative stress which further 
enhances AMPK signaling.165 Moreover, increased AMPK 
activity also impaired the normal subcellular distribution of 
FUS, highlighting the critical role of AMPK-mediated patho-
genicity in ALS.167 Supporting these results, pharmacological 
or genetic downregulation of the AMPK pathway resulted in 
decreased TDP-43 mislocalization and delayed neurodegen-
eration progression in NSC-34 cells or C. elegans models of 
disease.165,168 However, Perera et al. (2014) showed contradic-
tory findings, suggesting that mutant TDP-43 inhibits AMPK 
activity by positively acting on AMPK phosphatase and pro-
tein phosphatase 2A, two critical negative regulators of 
AMPK.169 As the later experiments were performed on a 
transgenic model of TDP-43-associated ALS, these contrast-
ing results might be attributed either to different methodolo-
gies or to differences in the biological systems used or mutation 
investigated. Interestingly, in Perera’s study (2014), the SOD1 
cohort reported a sharp increase in AMPK phosphorylation at 
disease onset. These contrasting results between the TDP-43 
group and the SOD1 mice might reflect distinct pathogenic 
mechanisms or important differences in energy metabolism 
between these highly prevalent genetic causes of ALS.
Indeed, when it comes to SOD1 pathology, the evidence so 
far converges toward a consensus which suggests the presence 
of enhanced activation of the AMPK energy sensor in both cell 
lines and animal models of disease,164,168 as well as ALS 
patients.165 Surprisingly, however, stimulation of AMPK sign-
aling in SOD1 models has led to conflicting results. Metformin-
mediated activation of AMPK accelerated symptom onset and 
disease progression in SODI mice,170 whereas AMPK activa-
tion as a result of resveratrol administration showed beneficial 
effects on motor function and lifespan.171 A possible explana-
tion to support the later finding comes from previous studies 
which showed that resveratrol acts on the NAD-dependent 
deacetylase sirtuin-1 to activate the AMPK in a dose depend-
ent manner,172 which further deacetylates and positively regu-
lates PGC-1D.173 As PGC-1D is a co-activator of the nuclear 
respiratory factors and crucial regulator of mitochondrial bio-
genesis,174 AMPK may consequently improve mitochondrial 
function in skeletal muscles. However, it is important to note 
the characteristic differences between cellular respiration in 
skeletal muscles and neuronal metabolism, and to interpret the 
aforementioned findings keeping in mind that AMPK modu-
lation might have different effects in oxidative muscle fibers 
compared to glycolytic neuronal cells. To support this thought, 
no changes in PGC-1D were observed in spinal cord neuron 
cultures as a result of AMPK activity modulation, further 
emphasizing that any cellular changes observed might differ 
between cell-types or could be lost in whole tissue 
preparations.168
The detrimental effects of increased AMPK activity satisfy 
the expectations one might have when considering the possible 
downstream mechanisms of AMPK upregulation. Stimulating 
AMPK activity, which at the cellular level promotes glucose 
uptake and positively regulates FAO, could provide additional 
damage since both these pathways might be compromised in 
ALS, as discussed in the section above. In the same way, even 
though AMPK activation might have a positive contribution 
to turning on catabolic pathway in a healthy biological system, 
constant upregulation of AMPK signaling might become det-
rimental in the context of ALS pathology, in which high meta-
bolic demands are inflicted on neurons, energy stores are 
depleted and critical anabolic cascades are impaired. This pos-
sibly dual character of AMPK is supported by Coughlan et al. 
(2015)175 who highlights the benefits of a “preconditioning” 
approach when modulating AMPK function, suggesting that, 
while chronic activation of AMPK might be detrimental, sub-
threshold stimulation might increase tolerance for a potentially 
more robust future stress. Whether AMPK upregulation is 
beneficial or not, and how ALS pathogenesis affects this energy 
sensor remain two important open questions that need to be 
answered, but which encourage the existence of impaired 
energy homeostasis in ALS.
Metabolomics biomarkers in ALS
The well recognized presence of metabolic defects in the 
pathogenesis of ALS, along with the increasingly growing 
notion that ALS patients exhibit a hypermetabolic state1,8 has 
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brought the field of metabolomic research forward in the study 
of ALS, aiming to identify ALS-specific metabolites that could 
further represent physiological biomarkers of disease and 
which could possibly contour a metabolic signature for ALS.
So far, metabolomics analysis has proven effective in identi-
fying particular metabolic pathways affected in the disease pro-
gression, pathways which could then be targeted and 
compensated through therapeutic manipulation.176 Although 
metabolomic screening has been mainly focused on patients 
bearing mutations in SOD1 to the detriment of other genetic 
causes of ALS, in vitro and in vivo experiments shed some light 
on the association between TDP-43 pathology and metabolic 
alterations. A recent study in a Drosophila model of TDP-43-
associated ALS revealed a significant increase in long-chain 
fatty acid carnitine conjugates such as myristoylcarnitine, pal-
mitoylcarnitine, oleoylcarnitine and linoleoylcarnitine, in the 
context of both mutant and wild-type TDP-43 overexpres-
sion.148 In line with these observations, an important product 
of lipid beta oxidation, beta-hydroxybutyrate, along with the 
level of carnitine, a critical modulator of fatty acid transport 
across the mitochondrial membrane, were decreased in both 
experimental groups. Additional quantitative polymerase chain 
reaction (qPCR) analysis suggested that the expression of 
major units of the carnitine shuttle pathway was affected at the 
transcriptional level, pointing toward major defects in the 
mitochondrial carnitine shuttle system in the context of TDP-
43 pathology. These findings support data from clinical trials 
where low levels of carnitine have been reported in the blood 
and CSF of ALS patients,177,178 possibly correlating with the 
presence of amyotrophy, a primary ALS symptom. Similar 
alterations in lipid profiles have been previously reported in a 
cellular model of TDP-43, with polyunsaturated fatty acids 
(PUFA) and glycerophospholipids being particularly 
affected.179 However, these findings were recorded in the con-
text of wild-type TDP-43 overexpression, providing evidence 
for the toxic role of endogenous TDP-43, which will be dis-
cussed in detail below. Interestingly, comparable decreases in 
glycerophospholipids levels and matching alterations in PUFA 
concentrations had been formerly shown in a SOD1 transgenic 
model180 and ALS patients respectively.181 Moreover, lipidom-
ics analysis on the ALS mouse model bearing the SOD1-
G93A mutation distinguished altered phosphatidylcholine 
profiles in the cerebral cortex,182,183 possibly indicating a com-
mon pathogenic mechanism between TDP-43 and SOD1 tox-
icity. Similarly, high levels of free fatty acids and liquid droplets 
confirmed a defective lipid metabolism in iPSC-derived motor 
neurons from C9orf72 ALS patients,184 but it remains to be 
confirmed whether TDP-43 pathology could possess any 
active contribution to these metabolic defects.
Nevertheless, metabolomic analysis suggests that the detri-
mental effects of TDP-43 are not restricted to lipid metabo-
lism, but extends to other energy producing pathways as well, 
encompassing metabolic cascades like glycolysis in their 
pathogenicity. A recently published study performed in the 
same ALS-TDP-43 Drosophila model revealed increased levels 
of glycolytic metabolites such as phosphoenolpyruvate, pyru-
vate and sedoheptulose-7-phosphate in whole larvae, possibly 
indicating a pronounced glycolytic input into the pentose 
phosphate pathway as an attempt to mitigate oxidative stress 
through increased NADPH production.138 These results are 
consistent with elevated plasma pyruvate levels reported in 
ALS patients.185 Further analysis on patients derived iPSC 
motor neurons and transcriptional profiling of ALS spinal cord 
suggested a significant upregulation of phosphofructokinase-1 
levels, confirming an increased glycolytic flux in the context of 
TDP-43 pathology.138 Similar changes in metabolites profile 
were reported in NSC-34 cells expressing mutant SOD1-
G93A as well, where increased lactate, alanine and formate lev-
els in the medium were indicative of pronounced glycolysis.147 
Interestingly, this imbalance in ATP homeostasis could explain 
recent findings from sporadic ALS patients’ fibroblasts which 
showed alterations in purine and pyrimidine metabolism. The 
authors suggested that a disturbance in ATP production or 
abnormally elevated ATP consumption rates could lead to sig-
nificant changes in the serum profiles of purines, since these 
compounds are directly connected to ATP synthesis. Similarly, 
recent work from our laboratory discovered defects in purine 
metabolism, specifically adenosine, in astrocytes derived from 
sporadic and C9orf72 ALS cases due to loss of adenosine 
deaminase.137,160 It remains to be seen whether purine/pyrimi-
dine metabolism is affected in TDP43 cases. However, the fact 
that nucleoside defects are observed in C9orf72 and sporadic 
ALS cases of disease, indicate a common pathogenic mecha-
nism of disease that warrants further research including the 
possibility of targeted nutritional supplementation.
The studies discussed above provide evidence for the crucial 
contribution of metabotype information to identifying bio-
chemical pathways that are affected in ALS patients. 
Furthermore, by comparing the metabolic state at baseline with 
that measured after the administration of a proposed drug or 
therapy, scientists could improve their knowledge regarding 
treatment outcomes and better assess the drugresponse.186
TDP-43 mutations—a requisite of TDP-43 
pathology? he contribution of wild-type TDP-43 to 
neurodegeneration
Although the involvement of TDP-43 mutations in ALS 
pathogenesis cannot be contested, just a considerably small 
percentage of ALS cases are familial, and many other neuro-
degenerative disorders report the existence of TDP-43 pathol-
ogy in the absence of known TARDBP mutations.187,188 We 
have so far established the critical roles TDP-43 possess dur-
ing the shift of homeostatic balance into progressive neurode-
generation, but we have not yet addressed the question of 
whether there is a difference in functional activity between 
wild-type and mutant TDP-43, and whether mutations in the 
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TARDBP gene are considerably more pathogenic than the 
wild-type form.
Genetic upregulation of wild-type TDP-43 showed rapid 
formation of cytoplasmic aggregates in bacteria and yeast, 
along with a sharp decrease in growth rate, changes in mor-
phology and even cell death in yeast.189,190 Earlier studies in 
mouse models have reported that overexpression of wild-type 
human TDP-43 facilitated the accumulation of TDP-43 in 
nuclear and cytoplasmic aggregates, which further resulted in 
cortical and spinal neuronal degeneration accompanied by 
spastic paralysis.37 TDP-43 phosphorylation and aggregation 
in the spinal cord was again described in another transgenic 
mouse model overexpressing human TDP-43,126 along with a 
dose-dependent downregulation of mouse TDP-43. 
Interestingly, abnormal accumulation of mitochondria within 
motor neurons was also measured by Xu et al. (2010), indicat-
ing possible deficits in axonal transport machinery in the 
human TDP-43 cohort. Moreover, the findings reported an 
increased expression of two crucial components of mitochon-
drial fission machinery, dynamin-like protein and mitochon-
drial fusion 1 protein (DNM1L), which was accompanied by a 
downregulation of mitofusin 1 (MFN1), a major player in 
mitochondrial fusion. In the light of these results, it may be 
possible that the post-translational modifications of TDP-43 
come prior to mitochondrial clustering in disease progression. 
However, the TDP-43 phosphorylated inclusions were pri-
marily located in the spinal cord, and more sparsely in the 
brain, possibly suggesting that the effects of human TDP-43 
expression depend on the anatomic region and the biochemical 
context in which it is expressed. More recent studies compared 
the independent expression of human wild type TDP-43 
(TDP-43 wt) and the expression of Q331K mutant (TDP-43 
Q331K) against the co-expression of wild-type and mutant 
form (TDP-43 WTxQ331K).191 Surprisingly, the TDP-43 
WT group did not show any clinical or pathological pheno-
type, whereas the mutant cohort reported cytoplasmic accumu-
lation of TDP-43 along with mild neuronal loss and glial 
activation in the spinal cord and the motor cortex. When ana-
lyzing the mixed group, however, an extremely aggressive motor 
phenotype was reported, with significant reactive gliosis and 
neurodegeneration in the cortex and spinal cord, and promi-
nent TDP-43, p62 and ubiquitin cytoplasmic inclusions. Taken 
together, the results of the study indicate that, while the expres-
sion of human TDP-43 is not lethal on its own, its destructive 
effects could be profoundly accentuated by the presence of a 
pathogenic mutation, and that cytoplasmic accumulation of 
TDP-43 is sufficient to lead to neurodegeneration, without the 
contribution of loss of nuclear function. On the other hand, it 
may be possible that the wild-type TDP-43 contributes in a 
dose-dependent manner to neuronal toxicity by reinforcing the 
aggressive pathogenic activity of mutant TDP-43. This para-
digm is confirmed and reinforced by further studies in mam-
malian models, which showed sparse aggregation of TDP-43 
and surprisingly high levels of cytotoxicity, following overex-
pression of wild-type TDP-43.192,36 In an elegant study, 
Capitiniet al. (2014)193 used purified wild-type TDP-43 aggre-
gates derived from Escherichia coli and transfected them into 
SH-SY5Y cells, to allow a direct analysis of TDP-43 aggrega-
tion alone. The results showed elevated levels of ROS and cas-
pase-3 activation, along with a consequential significant 
decrease in viability. Interestingly, TDP-43 was not mislocal-
ized from the nucleus and did not aggregated into cytoplasmic 
inclusions, indicating that wild-type TDP-43, when overex-
pressed, is sufficient to induce cellular toxicity and ALS-like 
phenotypes, but, contrarily to TDP-43 mutants, the wild-type 
allele retains its nuclear localization and rarely aggregates. This 
hypothesis still needs to be confirmed as, so far, the research 
investigating the pathogenicity of wild-type TDP-43 shows 
conflicting results.
As recognized by previous studies, ALS-associated TDP-43 
mutations possess higher stability and show increased half-life 
compared to the wild-type form.194,195 Moreover, disease-
linked mutants are more rapidly turned over through the ubiq-
uitin/proteasome system (UPS) system than wild-type 
TDP-43,196 making it likely that such modifications are the 
driving factors that alter the processing and translation of the 
TDP-43’s mRNAs and facilitate its mislocalization and pre-
cipitation. Taken together, the studies discussed above advocate 
a possible pathogenic contribution of wild-type TDP-43 to 
disease progression in ALS. Whether the other genetic drivers 
of ALS have a similar function in their wild-type form goes 
beyond the scope of this review, but, considering its potential 
implications for research methodologies, such possibility 
should be further investigated in the future. Experimental con-
trol groups are crucial for validating the significance of the 
results, and selecting the right controls is a challenging task 
that can deeply influence the outcome of data analysis. Hence, 
it is crucial to consider the potential pathogenicity of WT pro-
teins when designing our chosen research methods in order to 
rule out any contribution of its activity.
Conclusions
Considering the solid circumstantial evidence discussed above, 
one can undoubtedly state that TDP-43 contributes majorly to 
metabolic dysfunction and energy defects in ALS pathogene-
sis. From changes in mitochondrial dynamics to alterations in 
metabolic profiles, TDP-43 pathology appears to integrate a 
wide spectrum of structural, morphological and functional 
defects. However, it is yet too early to conclude which is the 
precise origin of TDP-43 pathogenic signaling and how it dif-
fers from other ALS-associated genetic risks such as SOD1, 
FUS or C9orf72, as there are still major gaps in our current 
understanding of the underlying disease mechanisms. At the 
same time, it remains an open question of how different genetic 
causes of ALS can have opposing pathogenic activities regard-
ing some aspect of ALS pathogenesis, while still eventually 
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converging toward the same pathological outcome on motor 
neurons. Moreover, it is important to consider that, as ALS is a 
disease with a major detrimental effect on visceral and skeletal 
muscle, metabolic changes occurring at this level could provide 
great insights into what may be happening upstream, at higher 
cortical levels. In a recently published study, the levels of sar-
colipin, an important regulator of SERCA activity in muscle 
fibers, appeared to be upregulated in SOD1 transgenic mice,197 
triggering a mitochondrial reprogramming event which deter-
mines a transition of skeletal muscle for glycolytic to oxidative 
metabolism.198 Such modifications correlate well with some of 
the evidence discussed above, supporting the existence of met-
abolic dysfunction and early mitochondrial failure in ALS 
pathogenesis. However, future work is needed for an in-depth 
characterization of the systemic abnormalities associated with 
ALS, and an exhaustive understanding of these metabolic 
changes is crucial in terms of finding potential therapeutic 
strategies.
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